UK health technology assessor the National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending Forxiga (dapagliflozin) as an option to treat chronic ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

AstraZeneca Plc's (NASDAQ: AZN) dapagliflozin 5mg (Forxiga/Farxiga) was authorized in 2019 as an adjunct to insulin in patients with type 1 diabetes with a body-mass index (BMI) of 27 kg per m2.

The “somewhat unexpected” finding is likely related to the profound impact on health status from the procedure itself.

WILMINGTON, Del., June 12, 2024--(BUSINESS WIRE)--AstraZeneca’s FARXIGA ® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric ...

K.B. and J.J.G.S. are employees of AstraZeneca. The article, titled “Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD ...

AMSTERDAM — For patients hospitalized for acute heart failure, initiating treatment with the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) before hospital discharge was safe, it appeared ...

Dec 19 (Reuters) - AstraZeneca (AZN.L), opens new tab on Monday won European endorsement for its blockbuster drug, dapagliflozin, as a treatment for all forms of heart failure, the company said.

refused to grant AstraZeneca (“AZ”) an interim injunction to restrain Glenmark from launching in the U.K. a generic version of its type 2 diabetes treatment, Forxiga® (dapagliflozin ...

Hope that AstraZeneca's diabetes and heart failure ... The DARE-19 trial showed that giving Farxiga (dapagliflozin) to COVID-19 patients at risk of developing severe complications wasn’t able ...

AstraZeneca India has received the Central Drugs Standard Control Organization’s (CDSCO) approval for their anti-diabetic drug dapagliflozin in the treatment of adults with chronic kidney disease (CKD ...

In a reversal of fortune, yesterday (9 April) the UK Court of Appeal awarded AstraZeneca (AZ) an interim injunction keeping Glenmark’s dapagliflozin (dapa) off the UK market until the form of ...